$VITR #Vitrolife AB Vitrolife - Demand is slowly recovering: Sales declined by 45% in Q2, likely the demand trough Firm expects COVID-19 headwinds to persist into H2 We lower EBIT by 2-11%; ’21e EV/EBIT of 44x https://t.co/SXeZt5BmGp #equity #stocks https://t.co/Q2htsOmWw3